<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04080856</url>
  </required_header>
  <id_info>
    <org_study_id>P19-933</org_study_id>
    <nct_id>NCT04080856</nct_id>
  </id_info>
  <brief_title>Real-World Experience Study of Elagolix For the Treatment of Endometriosis in Canada</brief_title>
  <acronym>GRACE</acronym>
  <official_title>Real-World Experience of Elagolix For the Treatment of Endometriosis in Canada: An Observational Cohort Study (GRACE)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to evaluate real-world effectiveness of elagolix in Canadian
      women with endometriosis.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">December 9, 2019</start_date>
  <completion_date type="Anticipated">May 26, 2023</completion_date>
  <primary_completion_date type="Anticipated">May 26, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Dysmenorrhea Score</measure>
    <time_frame>From Baseline (Month 0) to Month 6</time_frame>
    <description>Dysmenorrhea is evaluated through 11-point numeric rating scale (NRS), where 0 = no pain and 10 = worst imaginable pain</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Patient Global Impression of Change (PGIC) Response</measure>
    <time_frame>Up to approximately 18 months</time_frame>
    <description>PGIC is a questionnaire-based assessment of endometriosis-related pain is since initiation of study drug.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Clinician's Global Impression of Change (CGIC) Response</measure>
    <time_frame>Up to approximately 18 months</time_frame>
    <description>CGIC score is summarized assessment of clinical diagnosis of patient's illness by clinician in relative to a baseline state.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Non-Menstrual Pelvic Pain (NMPP)</measure>
    <time_frame>From Baseline (Week 0) to approximately 18 months</time_frame>
    <description>The NMPP pain scale ranges from 0 (none) to 3 (severe) as recorded in a daily electronic diary.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Dyspareunia Score</measure>
    <time_frame>From Baseline (Week 0) to approximately 18 months</time_frame>
    <description>Dyspareunia pain scale ranges from 0 (absent) to 3 (severe).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Pelvic Pain During Periods</measure>
    <time_frame>From Baseline (Week 0) to approximately 18 months</time_frame>
    <description>Change in pelvic pain is patient reported questionnaire to rate the severity of pelvic pain during periods on the scale of 0 to 10, where 0 = no pain and 10 = worst imaginable pain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Bleeding and Menstrual Cycle</measure>
    <time_frame>From Baseline (Week 0) to approximately 18 months</time_frame>
    <description>Uterine bleeding was reported by participants during the study using the e-Diary.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Change in Dosing Schedule</measure>
    <time_frame>Up to approximately 18 months</time_frame>
    <description>Percentage of participants who change dose as well as the reasons for change will be tabulated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Morisky Medication Adherence Scale (MMAS)</measure>
    <time_frame>From Baseline (Week 0) to approximately 18 months</time_frame>
    <description>The Morisky Medication Adherence Scale (MMAS) is a 4-item questionnaire assessing the risk of non-adherence to medications.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Using Concomitant Medications/Treatments</measure>
    <time_frame>Up to approximately 18 months</time_frame>
    <description>Percentage of participants using concomitant medications/treatments is assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Using Other Medications/Treatments</measure>
    <time_frame>Up to approximately 18 months</time_frame>
    <description>Percentage of participants using other medications/treatments for endometriosis is assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Using Pain/Rescue Medications</measure>
    <time_frame>Up to approximately 18 months</time_frame>
    <description>Percentage of participants using pain/rescue medications is assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Using Add-Back</measure>
    <time_frame>Up to approximately 18 months</time_frame>
    <description>Percentage of participants with use of add-back is reported</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Endometrial Health Profile (EHP)-30</measure>
    <time_frame>From Baseline (Week 0) to approximately 12 months</time_frame>
    <description>EHP-30 is a disease-specific self-administered questionnaire used to measure health related QoL in women with endometriosis. EHP-30 covers 5 dimensions: pain, control and powerlessness, social support, emotional wellbeing, and self-image.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Endometrial Health Profile (EHP)-5</measure>
    <time_frame>Up to approximately 6 months post-treatment (Month 12)</time_frame>
    <description>EHP-5 is a disease-specific self-administered questionnaire used to measure health related QoL in women with endometriosis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Work Productivity and Activity Impairment (WPAI)</measure>
    <time_frame>From Baseline (Week 0) to approximately 18 months</time_frame>
    <description>WPAI questionnaire is used to measure the effect of general health and symptom severity on work productivity and regular activities during the past seven days.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Endometriosis</condition>
  <arm_group>
    <arm_group_label>Participants with endometriosis</arm_group_label>
    <description>Premenopausal participants with endometriosis receiving elagolix in real-world setting</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Premenopausal participants with endometriosis
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Prescribed elagolix as part of standard treatment

          -  Naive to elagolix prior to starting this study or have stopped taking elagolix for 2
             months prior to the start of this study

          -  Symptomatic endometriosis (clinically or surgically diagnosed) including currently
             experiencing dysmenorrhea

          -  Has provided written informed consent allowing the use of their data for the study

        Exclusion Criteria:

          -  Did not consent

          -  Cannot fill out questionnaires

          -  Prescribed elagolix for a period of 1 or 2 months only

          -  Post-menopausal (naturally or surgically)

          -  Symptomatic uterine fibroid(s)

          -  Had medical treatment for uterine fibroids (any length of treatment)
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>AbbVie Inc.</last_name>
    <role>Study Director</role>
    <affiliation>AbbVie</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>ABBVIE CALL CENTER</last_name>
    <phone>847.283.8955</phone>
    <email>abbvieclinicaltrials@abbvie.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Calgary /ID# 212942</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2E 7W7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>South Health Campus /ID# 213065</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T3M 1M4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Aubrey D. Uretsky Professional Corporation /ID# 214753</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T5T 1L6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>BC Women's Hospital /ID# 214561</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6H 2N9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Strand Clinic /ID# 213567</name>
      <address>
        <city>St. John's</city>
        <state>Newfoundland and Labrador</state>
        <zip>A1A 4Y3</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>IWK Health Center /ID# 213066</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3K 6R8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>McMaster University Med Cent /ID# 213496</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8S 4K1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Dr. George A. Vilos Medicine Professional Corporation /Id# 214497</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N5X 2N7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Ottawa Hospital /ID# 213608</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 8L6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Medicor Research Inc. /ID# 213467</name>
      <address>
        <city>Sudbury</city>
        <state>Ontario</state>
        <zip>P3E 5M4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sunnybrook Health Sciences Cen /ID# 214330</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4N 3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Unity Health Toronto /ID# 213590</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5B 1W8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Hosp.-Toronto /ID# 214023</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 1X5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hopital Gatineau CISSSO /ID# 212944</name>
      <address>
        <city>Gatineau</city>
        <state>Quebec</state>
        <zip>J8P 7H2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre de Gyn-écologie et Maternité /ID# 212943</name>
      <address>
        <city>Lasalle</city>
        <state>Quebec</state>
        <zip>H8N 1T9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinique de Gynecologie-Obstetrique Pierre Boucher /ID# 213064</name>
      <address>
        <city>Longueuil</city>
        <state>Quebec</state>
        <zip>J4N 1C2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Jewish General Hospital /ID# 215728</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3T 1E2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>CIUSSS de l'Est de l'Ile de Montréal /ID# 213439</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <zip>H1T 2M4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Brunswick Medical /ID# 214743</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <zip>H4A 3T2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU de Quebec-Université Laval /ID# 213677</name>
      <address>
        <city>Québec</city>
        <state>Quebec</state>
        <zip>G1V 4G2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Dr. John A. Thiel Medecine Professional Corporation /ID# 213766</name>
      <address>
        <city>Regina</city>
        <state>Saskatchewan</state>
        <zip>S4S 6X3</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <link>
    <url>http://www.rxabbvie.com</url>
    <description>Related Info</description>
  </link>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>September 4, 2019</study_first_submitted>
  <study_first_submitted_qc>September 5, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 6, 2019</study_first_posted>
  <last_update_submitted>December 4, 2019</last_update_submitted>
  <last_update_submitted_qc>December 4, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 5, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Endometriosis</keyword>
  <keyword>Elagolix</keyword>
  <keyword>Real-World</keyword>
  <keyword>Effectiveness</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Endometriosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

